



October 30, 2015

FOR IMMEDIATE RELEASE

Company name: U M N P h a r m a I n c .
 Representative: Chairman and CEO Tatsuyoshi Hirano
 Securities code: 4585
 Contact person: CFO Hiroyuki Hashimoto
 (T E L) + 8 1 - 4 5 - 5 9 5 - 9 8 4 0

**UMN Pharma Announces Revision of Consolidated Financial Results Forecasts
 For the Fiscal Year Ending December 31, 2015**

UMN Pharma Inc. (“the Company”) announced today that based on recent developments in business, the Company has revised its full-year consolidated financial results forecasts for the fiscal year ending December 31, 2015 (from Jan. 1, 2015 to Dec. 31, 2015) from those previously announced on June 5, 2015.

1. Revised full-year consolidated financial results forecasts for the fiscal year ending December 31, 2015 (from Jan. 1, 2015 to Dec. 31, 2015)

	Net sales	Operating income (loss)	Ordinary income (loss)	Net income (loss)	Net income (loss) per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previously announced forecasts (A) (June 5, 2015)	2,254	(1,697)	(1,844)	(1,852)	(193.54)
Revised forecasts (B)	222	(3,224)	(3,404)	(3,405)	(355.87)
Change (B-A)	(2,032)	(1,527)	(1,559)	(1,553)	—
Rate of change (%)	(90.1)%	—	—	—	—
(Ref.) Results for the fiscal year ended Dec. 31, 2014	1,108	(3,942)	(4,249)	(3,961)	(452.34)

2. Reason for revision of the consolidated financial results forecasts

As for UMN-0502 (recombinant influenza HA vaccine for the prevention of seasonal influenza, hereinafter referred to as “UMN-0502”), of which Astellas Pharma Inc. (“Astellas”) submitted an application for marketing approval for the prevention of influenza to the Ministry of Health, Labour and Welfare in May, 2014, the Company, in collaboration with Astellas, has continued to respond to the related inquiries from Pharmaceutical and Medical Agency (“PMDA”) for the review process. Judging from the current progress on the review, the Company has concluded that it will take at least some more time than previously anticipated before gaining the approval, and that posting the milestone sales from Astellas, which was projected in the previous financial results forecasts, would be realized during the fiscal year ending December 31, 2016. Also taking into account the previously anticipated sales from currently delayed biopharmaceutical contract manufacturing projects, the Company has decided to revise downward consolidated financial results forecasts for the fiscal year ending December 31, 2015 announced on June 5, 2015, as shown in the above table.

On the other hand, total expenses during the period are expected to decrease compared to those counted in the previous forecasts, as the royalty payable to Protein Sciences Corporation with regard to the anticipated milestone receivable from

Astellas is to be incurred during the next fiscal year and the selling, general and administrative expenses are forecasted to decrease due to the Company's efforts towards further cost reduction at Gifu plant, while some R&D expenses regarding PMDA's review are expected to increase.

As a result, consolidated operating loss, ordinary loss and net loss for the fiscal year ending December 31, 2015, are forecasted to widen compared to those announced on June 5, 2015, as the Company's efforts to reduce expenses could not make up for the decrease in net sales.

In "Supplement Documents for Financial Results for First half of FY 2015 Ending Dec. 31, 2015" disclosed on July 31, 2015, the Company disclosed "FY 2015 - FY2018 Mid-term Business Plan : Financial Targets" on page 29 of the material, based on the assumption that the commercial manufacturing and shipment of UMN-0502 would start from 2016 – 2017 season. The Company has not changed that assumption. As for the financial results forecasts for fiscal year ending December 31, 2016, the milestone sales from Astellas and the other sales from biopharmaceutical manufacturing business, which have caused the downward revision for financial results forecasts for the year ending December 31, 2015, are expected to be added. The Company will disclose financial results forecasts of fiscal year 2016 and mid-term financial targets after thorough examination of other influential factors, such as the one regarding the project to export Flublok[®] (same as UMN-0502) drug substances manufactured at Gifu plant to the U.S. currently under way.

(Note)

The above financial forecasts are based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Consequently, any statements herein do not constitute assurances regarding the actual results. Actual financial results may differ materially depending on a number of factors.